ArticleFrontiers in pharmacology2026
Single-cell and spatial dissection of IGF2BP3-driven endothelial reprogramming underlying microvascular invasion in hepatocellular carcinoma.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Targeting IGF2BP3 in Cancer: From Molecular Structure and Biology to Early Drug Discovery.International journal of molecular sciences · 2026Review
- Analytical Methods and Application of Single-Cell and Single-Nucleus Transcriptomics in the Study of Ischemic Stroke.Biomolecules · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Microvascular invasion (MVI) is a critical determinant of early recurrence and poor prognosis in hepatocellular carcinoma (HCC). The cellular and molecular mechanisms driving MVI, particularly the role of endothelial heterogeneity, remain incompletely understood. Methods: We integrated single-cell and spatial transcriptomics from multiple HCC cohorts to identify MVI-associated endothelial subpopulations. GeneNMF and hdWGCNA were applied to define stable gene modules, while CellChat and NicheNet analyzed intercellular signaling. Prognostic relevance was assessed using machine learning-based risk models across TCGA-LIHC and external datasets. Functional assays including EdU proliferation, tube formation, and Western blot were conducted to validate the role of IGF2BP3 in tumor-associated endothelial cells. Results: We identified a distinct MVI-associated endothelial subpopulation (MVI Endo) enriched in pro-angiogenic, EMT-like, and TGF-β-responsive pathways, predominantly localized near tumor vasculature. MVI Endo engaged in robust VEGF, ANGPT2, and TGF-β signaling with tumor and stromal cells. Machine learning-derived prognostic models highlighted IGF2BP3 as a central regulator, and functional assays demonstrated that IGF2BP3 enhances endothelial proliferation and tube formation via upregulation of VEGF-A and ANGPT2, supporting its involvement in the vascular phenotype associated with MVI. Conclusion: This study characterizes the endothelial landscape associated with MVI, implicates IGF2BP3 as a critical regulator of vascular reprogramming, and provides a foundation for precision vascular-targeted therapies in HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.